RAD001: Clinical Trials

155 trials of RAD001, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

103 completed, 30 terminated, 8 unknown, 6 active not recruiting. 155 Phase 2, 43 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2155Completed 103, Terminated 30, Unknown 8, Active not recruiting 6, Withdrawn 5, Recruiting 2, Not yet recruiting 1
Phase 143Completed 31, Terminated 10, Unknown 1, Withdrawn 1
Phase 31Unknown 1

Follow RAD001: new trials by email Literature Review of RAD001 trials Research Report on RAD001

Trials (filtered) newest first · largest first

All 155 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer
Biospecimen Collection, Computed Tomography, Elacestrant - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma
Phase 2Not yet recruitingJonsson Comprehensive Cancer Center502026-12-182026-06-09
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
Biospecimen Collection, Cabozantinib, Computed Tomography - Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2
Phase 2RecruitingNational Cancer Institute (NCI)1002024-01-122026-11-12
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Biospecimen Collection, Computed Tomography, Everolimus - Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor
Phase 2RecruitingNational Cancer Institute (NCI)702023-02-032026-11-12
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
Cabozantinib, Everolimus, Lenvatinib - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
Phase 2Active not recruitingM.D. Anderson Cancer Center902022-02-162026-09-14
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
Everolimus, Lenvatinib - Advanced Carcinoid Tumor, Digestive System Neuroendocrine Neoplasm
Phase 2Active not recruitingM.D. Anderson Cancer Center362019-07-302026-09-18
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
Everolimus, Exemestane, Everolimus Placebo - Advanced Breast Cancer
Phase 2CompletedNovartis Pharmaceuticals1592017-09-152024-01-23
A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
Everolimus, Letrozole, Ribociclib - Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma
Phase 2Active not recruitingM.D. Anderson Cancer Center902017-08-182026-11-10
Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Ribociclib, Everolimus - Soft Tissue Sarcoma
Phase 2Active not recruitingFox Chase Cancer Center482017-08-082026-05-22
RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome
RAD001, Placebo - PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome
Phase 1 / Phase 2CompletedBoston Children's Hospital462017-06-122025-02-17
A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer
Everolimus, Letrozole, Fluorouracil - Breast Cancer
Phase 2CompletedSun Yat-Sen Memorial Hospital of Sun Yat-Sen University402016-06-012021-09-23
Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
Bevacizumab, Everolimus, Laboratory Biomarker Analysis - Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma
Phase 2CompletedM.D. Anderson Cancer Center172016-01-122024-02-13
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
Everolimus - Solid Malignancy, Solid Tumor
Phase 2CompletedWashington University School of Medicine122015-10-072018-10-02
Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer
Everolimus, Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System - Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
Phase 2Active not recruitingM.D. Anderson Cancer Center1022015-09-232026-09-10
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
Everolimus, Tamoxifen, Letrozole - Advanced, Persistent, or Recurrent Endometrial Cancer
Phase 2CompletedGOG Foundation742015-05-212024-09-19
Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors
everolimus - Solid Tumor
Phase 2CompletedSamsung Medical Center102015-02-012017-02-17
Everolimus trIal for Advanced prememopausaL Breast Cancer Patients
Everolimus, Goserelin, Letrozole - Metastatic Breast Cancer
Phase 2UnknownChinese Academy of Medical Sciences2002014-12-012014-12-09
Phase II Study of Everolimus Beyond Progression
everolimus, anastrozole, letrozole - Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Phase 2TerminatedEmory University32014-11-252022-04-05
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Everolimus, Laboratory Biomarker Analysis, Letrozole - Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma
Phase 2CompletedMayo Clinic202014-11-142020-10-23
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Everolimus - Estrogen Receptor-positive Breast Cancer, Gastrinoma
Phase 2TerminatedEmory University22014-11-012017-02-03
Everolimus for Cancer With TSC1 or TSC2 Mutation
Everolimus - TSC1, TSC2
Phase 2CompletedDana-Farber Cancer Institute302014-09-012020-09-16

Showing 20 of 155. Sign in to see all of them.

Conditions studied

Breast Neoplasms (26)  ·  Carcinoma, Renal Cell (16)  ·  Kidney Neoplasms (10)  ·  Neoplasm Metastasis (9)  ·  Lymphoma, Mantle-Cell (7)  ·  Tuberous Sclerosis (7)  ·  Carcinoma, Hepatocellular (6)  ·  Hodgkin Disease (6)  ·  Pancreatic Neoplasms (6)  ·  Prostatic Neoplasms (6)  ·  Sarcoma (6)  ·  Colorectal Neoplasms (5)  ·  Liver Neoplasms (5)  ·  Lymphoma (5)  ·  Neoplasms (5)

Sponsors

Novartis Pharmaceuticals (19)  ·  M.D. Anderson Cancer Center (18)  ·  Dana-Farber Cancer Institute (10)  ·  Emory University (6)  ·  National Cancer Institute (NCI) (6)  ·  SCRI Development Innovations, LLC (6)  ·  Mayo Clinic (5)  ·  Children's Hospital Medical Center, Cincinnati (4)  ·  Swiss Cancer Institute (4)  ·  Asan Medical Center (3)  ·  Seoul National University Hospital (3)  ·  GOG Foundation (2)  ·  Jonsson Comprehensive Cancer Center (2)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2)  ·  The Methodist Hospital Research Institute (2)

Countries

United States (117)  ·  France (12)  ·  Germany (10)  ·  South Korea (10)  ·  Italy (9)  ·  Spain (7)  ·  Argentina (6)  ·  Australia (6)  ·  Belgium (6)  ·  Netherlands (6)  ·  Brazil (5)  ·  Canada (5)  ·  China (5)  ·  Denmark (5)  ·  Thailand (5)

Top investigators

Amado Zurita, MD (2)  ·  Jean-Francois Dufour, MD (2)  ·  John D. Hainsworth, M.D. (2)  ·  Mustafa Sahin, MD, PhD (2)  ·  Robert J Amato, DO (2)  ·  Sunil Sharma, MD (2)  ·  Yung-Jue Bang, MD, PhD (2)  ·  A P Chen (1)  ·  Amanda Townsend, MBBS (1)  ·  Amy Tiersten, MD (1)  ·  Andrew W Hahn, MD (1)  ·  Andrew X. Zhu, MD, PhD (1)  ·  Angus A Wilfong, MD (1)  ·  Anjali Advani, MD (1)

Results publications

PMID 19192962, PMID 21730275, PMID 19047305, PMID 19549709, PMID 19745764, PMID 20368560, PMID 20564157, PMID 20630061, PMID 21047224, PMID 21410393, PMID 22262746, PMID 22315486, PMID 22928480, PMID 23180114, PMID 23325902, PMID 23580238, PMID 23582881, PMID 23798472, PMID 23969699, PMID 24037083, PMID 24156027, PMID 24327334, PMID 24332215, PMID 24669015, PMID 24684785, PMID 25049330, PMID 25103371, PMID 25361980, PMID 25362970, PMID 25426617, PMID 25450031, PMID 25498219, PMID 26025965, PMID 26113676, PMID 26139427, PMID 26381530, PMID 26602013, PMID 26681676, PMID 26884590, PMID 27680407, PMID 27836860, PMID 28327953, PMID 28330462, PMID 29023494, PMID 29070044, PMID 29074099, PMID 29234922, PMID 29454306, PMID 29566104, PMID 29664714

NIH funding

2009 (2), P30CA015083 (2), U10CA180821 (2), 2008 (1), K23CA121994 (1), N01CM00038 (1), N01CM00039 (1), N01CM62202 (1), P30CA008748 (1), P30CA016672 (1), P30CA043703 (1), P30CA072720 (1), P50CA098258 (1), R01FD003743 (1), U01CA069856 (1)